locoregional treatment

OTHER2 trials

Sponsors

UNICANCER, National Cancer Institute, Egypt

Conditions

Breast CancerBreast Cancer Stage IVMetastatic Breast CancerMetastatic CancerRadiotherapySurgery

Unknown Phase

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

Active, not recruitingNCT03870919

UNICANCERBreast Cancer Stage IV, Radiotherapy, Surgery

Start: 2019-10-23End: 2027-10-23Updated: 2024-09-19

Metastases Directed Therapy for Oligometastatic Breast Cancer

RecruitingNCT06144346

National Cancer Institute, EgyptBreast Cancer, Metastatic Breast Cancer, Metastatic Cancer

Start: 2023-09-20End: 2028-09-20Target: 150Updated: 2023-11-22

Related Papers

Abstract PS1-09-08: Impact of locoregional treatment after 6 months of palbociclib + letrozole combination therapy in de novo er+, her2- metastatic breast cancer patients: first results of the prospective palatine trial

Clinical Cancer Research2026-02-17